Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis

Eligibility Criteria

• * Diagnosis of active UC defined on clinical grounds (Partial Mayo score ≥ 3 with each subscore \>1)
• * Sexually active male and female subjects of childbearing potential must agree to use an effective method of birth control during the study.
• * Female subjects of childbearing potential must have a negative urine Qualitative Human Chorionic Gonadotropin(HCG)pregnancy test at enrolment and on the Week 1, Day 1 of the Treatment prior to administration of study drug.
• * Willing and able to sign an informed consent form and attend all study-related clinic visits, assessments, and follow-up phone calls.
• * Subject has an attending physician who will provide the non-FMT care.
• * Subjects with sever UC (Mayo score of \>7)
• * Unable to take retention enema or multiple capsules orally.
• * Females who are pregnant, breastfeeding, or planning to become pregnant during the study.
• * Receipt of systemic non-topical antibiotics within 14 days of treatment day 1.
• * Positive results for active HIV, Hepatitis B, or Hepatitis C infections.
• * History of recurrent Clostridium difficile infection or FMT in the past 6-months.
• * History of other active gastrointestinal conditions such as irritable bowel syndrome, microscopic colitis, celiac disease, short gut syndrome, colostomy, colectomy, gastrointestinal fistulae or strictures, chronic parasitic infections, diverticulitis etc.
• * Known history of bile acid diarrhea
• * Compromised immune system (e.g. primary immune disorders or clinical immunosuppression due to a medical condition or medication e.g. taking oral prednisone \>20 mg a day or prednisone-equivalent)
• * History of active cancer and/or ongoing chemotherapy (superficial non-metastatic cancers and maintenance chemotherapy are permitted).
• * History of use of an investigational drug within 90 days prior to the screening visit.
• * History of significant uncontrolled systemic disease that in the opinion of the study investigator could interfere with study participation and/or objectives.
• * Life expectancy of \< 1 year.
• * In the opinion of investigator, subject for any reason, should be excluded from the study.
• * Absolute neutrophil count (ANC) \< 500IU/mL